

Aetna Better Health of Texas (ABHTX)

Dear Provider,

On 09/01/2024, the following Texas Medicaid Health Plan Policies will be implemented:

Genetic Codes:

• The following codes will deny if billed more than one (1) unit per date of service (DOS).

Code	Policy
81324	RUNX1 (runt related transcription factor 1) (eg, acute myeloid
	leukemia, familial platelet disorder with associated myeloid
	malignancy), gene analysis, targeted sequence analysis (eg, exons
	3-8)
81238	EZH2 (enhancer of zeste 2 polycomb repressive complex 2 subunit)
	(eg, myelodysplastic syndrome, myeloproliferative neoplasms) gene
	analysis, full gene sequence
81370	HLA Class I and II typing, low resolution (eg, antigen equivalents);
	HLA-A, -B, -C, -DRB1/3/4/5, and -DQB1
81371	HLA Class I and II typing, low resolution (eg, antigen equivalents);
	HLA-A, -B, and -DRB1 (eg, verification typing)
81372	HLA Class I typing, low resolution (eg, antigen equivalents);
	complete (ie, HLA-A, -B, and -C)
81374	HLA Class I typing, low resolution (eg, antigen equivalents); one
	antigen equivalent (eg, B*27), each
81378	HLA Class I and II typing, high resolution (ie, alleles or allele groups),
	HLA-A, -B, -C, and -DRB1
81379	HLA Class I typing, high resolution (ie, alleles or allele groups);
	complete (ie, HLA-A, -B, and -C)
81402	MOLECULAR PATHOLOGY PROCEDURE LEVEL 3
81407	MOLECULAR PATHOLOGY PROCEDURE LEVEL 7
81596	Infectious disease, chronic hepatitis C virus (HCV) infection, six
	biochemical assays (ALT, A2-macroglobulin, apolipoprotein A-1,
	total bilirubin, GGT, and haptoglobin) utilizing serum, prognostic
	algorithm reported as scores for fibrosis and necro inflammatory
	activity in liver
81120	IDH1 (isocitrate dehydrogenase 1 [NADP+], soluble) (eg, glioma),
	common variants (eg, R132H, R132C)
81121	DH2 (isocitrate dehydrogenase 2 [NADP+], mitochondrial) (eg,
	glioma), common variants (eg, R140W, R172M)
81168	CCND1/IGH (t(11;14)) (eg, mantle cell lymphoma) translocation
	analysis, major breakpoint, qualitative and quantitative, if performed

Code	Policy
81170	ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase) (eg,
	acquired imatinib tyrosine kinase inhibitor resistance), gene
	analysis, variants in the kinase domain
81175	ASXL1 (additional sex combs like 1, transcriptional regulator) (eg,
	myelodysplastic syndrome, myeloproliferative neoplasms, chronic
	myelomonocytic leukemia), gene analysis; full gene sequence
81176	ASXL1 (additional sex combs like 1, transcriptional regulator) (eg,
	myelodysplastic syndrome, myeloproliferative neoplasms, chronic
	myelomonocytic leukemia), gene analysis; targeted sequence
	analysis (eg, exon 12)
81206	BCR/ABL1 (t(9;22)) (eg, chronic myelogenous leukemia)
	translocation analysis; major breakpoint, qualitative or quantitative
81207	BCR/ABL1 (t(9;22)) (eg, chronic myelogenous leukemia)
	translocation analysis; minor breakpoint, qualitative or quantitative
81208	BCR/ABL1 (t(9;22)) (eg, chronic myelogenous leukemia)
	translocation analysis; other breakpoint, qualitative or quantitative
81210	BRAF (B-Raf proto-oncogene, serine/threonine kinase) (eg, colon
	cancer, melanoma), gene analysis, V600 variant(s)
81218	CEBPA (CCAAT/enhancer binding protein [C/EBP], alpha) (eg,
	acute myeloid leukemia), gene analysis, full gene sequence
81219	CALR (calreticulin) (eg, myeloproliferative disorders), gene analysis,
	common variants in exon 9
81233	BTK (Bruton's tyrosine kinase) (eg, chronic lymphocytic leukemia)
	gene analysis, common variants (eg, C481S, C481R, C481F)
81235	EGFR (epidermal growth factor receptor) (eg, non-small cell lung
	cancer) gene analysis, common variants (eg, exon 19 LREA deletion,
	L858R, T790M, G719A, G719S, L861Q)
81236	EZH2 (enhancer of zeste 2 polycomb repressive complex 2 subunit)
	(eg, myelodysplastic syndrome, myeloproliferative neoplasms) gene
	analysis, full gene sequence
81237	EZH2 (enhancer of zeste 2 polycomb repressive complex 2 subunit)
	(eg, diffuse large B-cell lymphoma) gene analysis, common
	variant(s) (eg, codon 646)
81245	FLT3 (fms-related tyrosine kinase 3) (eg, acute myeloid leukemia),
	gene analysis; internal tandem duplication (ITD) variants (ie, exons
	14, 15)
81246	FLT3 (fms-related tyrosine kinase 3) (eg, acute myeloid leukemia),
	gene analysis; tyrosine kinase domain (TKD) variants (eg, D835,
	1836)
81261	IGH@ (Immunoglobulin heavy chain locus) (eg, leukemias and
	lymphomas, B-cell), gene rearrangement analysis to detect
	abnormal clonal population(s); amplified methodology (eg,
	polymerase chain reaction)

Code	Policy
81262	IGH@ (Immunoglobulin heavy chain locus) (eg, leukemias and lymphomas, B-cell), gene rearrangement analysis to detect abnormal clonal population(s); direct probe methodology (eg, Southern blot)
81263	IGH@ (Immunoglobulin heavy chain locus) (eg, leukemia and lymphoma, B-cell), variable region somatic mutation analysis
81264	IGK@ (Immunoglobulin kappa light chain locus) (eg, leukemia and lymphoma, B-cell), gene rearrangement analysis, evaluation to detect abnormal clonal population(s)
81265	Comparative analysis using Short Tandem Repeat (STR) markers; patient and comparative specimen (eg, pre-transplant recipient and donor germline testing, post-transplant non-hematopoietic recipient germline [eg, buccal swab or other germline tissue sample] and donor testing, twin zygosity testing, or maternal cell contamination of fetal cells)
81267	Chimerism (engraftment) analysis, post transplantation specimen (eg, hematopoietic stem cell), includes comparison to previously performed baseline analyses; without cell selection
81270	JAK2 (Janus kinase 2) (eg, myeloproliferative disorder) gene analysis, p.Val617Phe (V617F) variant
81272	KIT (v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog) (eg, gastrointestinal stromal tumor [GIST], acute myeloid leukemia, melanoma), gene analysis, targeted sequence analysis (eg, exons 8, 11, 13, 17, 18)
81273	KIT (v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog) (eg, mastocytosis), gene analysis, D816 variant(s)
81275	KRAS (Kirsten rat sarcoma viral oncogene homolog) (eg, carcinoma) gene analysis; variants in exon 2 (eg, codons 12 and 13)
81276	KRAS (Kirsten rat sarcoma viral oncogene homolog) (eg, carcinoma) gene analysis; additional variant(s) (eg, codon 61, codon 146)
81278	IGH@/BCL2 (t(14;18)) (eg, follicular lymphoma) translocation analysis, major breakpoint region (MBR) and minor cluster region (mcr) breakpoints, qualitative or quantitative
81279	JAK2 (Janus kinase 2) (eg, myeloproliferative disorder) targeted sequence analysis (eg, exons 12 and 13)
81287	MGMT (O-6-methylguanine-DNA methyltransferase) (eg, glioblastoma multiforme) promoter methylation analysis
81305	MYD88 (myeloid differentiation primary response 88) (eg, Waldenstrom's macroglobulinemia, lymphoplasmacytic leukemia) gene analysis, p.Leu265Pro (L265P) variant
81310	NPM1 (nucleophosmin) (eg, acute myeloid leukemia) gene analysis, exon 12 variants

Code	Policy
81311	NRAS (neuroblastoma RAS viral [v-ras] oncogene homolog) (eg, colorectal carcinoma), gene analysis, variants in exon 2 (eg, codons
01010	12 and 13) and exon 3 (eg, codon 61)
81313	PCA3/KLK3 (prostate cancer antigen 3 [non-protein
	coding]/kallikrein-related peptidase 3 [prostate specific antigen]) ratio (eg, prostate cancer)
81315	PML/RARalpha, (t(15;17)), (promyelocytic leukemia/retinoic acid
	receptor alpha) (eg, promyelocytic leukemia) translocation analysis;
	common breakpoints (eg, intron 3 and intron 6), qualitative or
	quantitative
81316	PML/RARalpha, (t(15;17)), (promyelocytic leukemia/retinoic acid
	receptor alpha) (eg, promyelocytic leukemia) translocation analysis;
	single breakpoint (eg, intron 3, intron 6 or exon 6), qualitative or
	quantitative
81320	PLCG2 (phospholipase C gamma 2) (eg, chronic lymphocytic
	leukemia) gene analysis, common variants (eg, R665W, S707F,
	L845F)
81334	RUNX1 (runt related transcription factor 1) (eg, acute myeloid
	leukemia, familial platelet disorder with associated myeloid
	malignancy), gene analysis, targeted sequence analysis (eg, exons
	3-8)
81338	MPL (MPL proto-oncogene, thrombopoietin receptor) (eg,
	myeloproliferative disorder) gene analysis; common variants (eg,
	W515A, W515K, W515L, W515R)
81339	MPL (MPL proto-oncogene, thrombopoietin receptor) (eg,
	myeloproliferative disorder) gene analysis; sequence analysis, exon
	10
81340	TRB@ (T cell antigen receptor, beta) (eg, leukemia and lymphoma),
	gene rearrangement analysis to detect abnormal clonal
	population(s); using amplification methodology (eg, polymerase
	chain reaction)
81341	TRB@ (T cell antigen receptor, beta) (eg, leukemia and lymphoma),
	gene rearrangement analysis to detect abnormal clonal
	population(s); using direct probe methodology (eg, Southern blot)
81342	TRG@ (T cell antigen receptor, gamma) (eg, leukemia and
	lymphoma), gene rearrangement analysis, evaluation to detect
	abnormal clonal population(s)
81345	TERT (telomerase reverse transcriptase) (eg, thyroid carcinoma,
	glioblastoma multiforme) gene analysis, targeted sequence analysis
	(eg, promoter region)
81347	SF3B1 (splicing factor [3b] subunit B1) (eg, myelodysplastic
	syndrome/acute myeloid leukemia) gene analysis, common variants
	(eg, A672T, E622D, L833F, R625C, R625L)

Code	Policy
81348	SRSF2 (serine and arginine-rich splicing factor 2) (eg,
	myelodysplastic syndrome, acute myeloid leukemia) gene analysis,
	common variants (eg, P95H, P95L)
81357	U2AF1 (U2 small nuclear RNA auxiliary factor 1) (eg, myelodysplastic
	syndrome, acute myeloid leukemia) gene analysis, common variants
	(eg, S34F, S34Y, Q157R, Q157P)
81360	ZRSR2 (zinc finger CCCH-type, RNA binding motif and
	serine/arginine-rich 2) (eg, myelodysplastic syndrome, acute
	myeloid leukemia) gene analysis, common variant(s) (eg, E65fs,
	E122fs, R448fs)
81417	Exome (eg, unexplained constitutional or heritable disorder or
	syndrome); re-evaluation of previously obtained exome sequence
	(eg, updated knowledge or unrelated condition/syndrome)
81427	Genome (eg, unexplained constitutional or heritable disorder or
	syndrome); re-evaluation of previously obtained genome sequence
	(eg, updated knowledge or unrelated condition/syndrome)
81504	Oncology (tissue of origin), microarray gene expression profiling of >
	2000 genes, utilizing formalin-fixed paraffin-embedded tissue,
	algorithm reported as tissue similarity scores
81513	Infectious disease, bacterial vaginosis, quantitative real-time
	amplification of RNA markers for Atopobium vaginae, Gardnerella
	vaginalis, and Lactobacillus species, utilizing vaginal-fluid
	specimens, algorithm reported as a positive or negative result for
	bacterial vaginosis
81514	Infectious disease, bacterial vaginosis and vaginitis, quantitative
	real-time amplification of DNA markers for Gardnerella vaginalis,
	Atopobium vaginae, Megasphaera type 1, Bacterial Vaginosis
	Associated Bacteria-2 (BVAB-2), and Lactobacillus species (L.
	crispatus and L. jensenii), utilizing vaginal-fluid specimens,
	algorithm reported as a positive or negative for high likelihood of
	bacterial vaginosis, includes separate detection of Trichomonas
	vaginalis and/or Candida species (C. albicans, C. tropicalis, C.
	parapsilosis, C. dubliniensis), Candida glabrata, Candida krusei,
	when reported
81518	Oncology (breast), mRNA, gene expression profiling by real-time
	RT-PCR of 11 genes (7 content and 4 housekeeping), utilizing
	formalin-fixed paraffin-embedded tissue, algorithms reported as
	percentage risk for metastatic recurrence and likelihood of benefit
	from extended endocrine therapy
81535	Oncology (gynecologic), live tumor cell culture and
2.200	chemotherapeutic response by DAPI stain and morphology,
	predictive algorithm reported as a drug response score; first single
	drug or drug combination

Code	Policy
81539	Oncology (high-grade prostate cancer), biochemical assay of four proteins (Total PSA, Free PSA, Intact PSA, and human kallikrein-2 [hK2]), utilizing plasma or serum, prognostic algorithm reported as a probability score
81540	Oncology (tumor of unknown origin), mRNA, gene expression profiling by real-time RT-PCR of 92 genes (87 content and 5 housekeeping) to classify tumor into main cancer type and subtype, utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a probability of a predicted main cancer type and subtype
81551	Oncology (prostate), promoter methylation profiling by real-time PCR of 3 genes (GSTP1, APC, RASSF1), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a likelihood of prostate cancer detection on repeat biopsy
81554	Pulmonary disease (idiopathic pulmonary fibrosis [IPF]), mRNA, gene expression analysis of 190 genes, utilizing transbronchial biopsies, diagnostic algorithm reported as categorical result (eg, positive or negative for high probability of usual interstitial pneumonia [UIP])
81595	Cardiology (heart transplant), mRNA, gene expression profiling by real-time quantitative PCR of 20 genes (11 content and 9 housekeeping), utilizing subfraction of peripheral blood, algorithm reported as a rejection risk score

Genetic Codes:

• The following codes will deny if billed more than two (2) units per date of service (DOS).

Code	Policy
81373	HLA Class I typing, low resolution (eg, antigen equivalents); one
	locus (eg, HLA-A, -B, or -C), each
81377	HLA Class II typing, low resolution (eg, antigen equivalents); one
	antigen equivalent, each
81380	HLA Class I typing, high resolution (ie, alleles or allele groups); one
	locus (eg, HLA-A, -B, or -C), each
81383	HLA Class II typing, high resolution (ie, alleles or allele groups); one
	allele or allele group (eg, HLA-DQB1*06:02P), each
81546	Oncology (thyroid), mRNA, gene expression analysis of 10,196 genes,
	utilizing fine needle aspirate, algorithm reported as a categorical
	result (eg, benign or suspicious)

Genetic Codes:

• The following codes will deny if billed more than three (3) units per date of service (DOS).

Code	Policy
81381	HLA Class I typing, high resolution (ie, alleles or allele groups); one
	allele or allele group (eg, B*57:01P), each

Genetic Codes:

• The following codes will deny if billed more than five (5) units per date of service (DOS).

Code	Policy
81376	HLA Class II typing, low resolution (eg, antigen equivalents); one locus (eg, HLA-DRB1, -DRB3/4/5, -DQB1, -DQA1, -DPB1, or -DPA1), each

Genetic Codes:

The following codes will deny if billed more than six (6) units per date of service (DOS).

Code	Policy
81382	HLA Class II typing, high resolution (ie, alleles or allele groups); one locus (eg, HLA-DRB1, -DRB3/4/5, -DQB1, -DQA1, -DPB1, or -DPA1), each

Genetic Codes:

• The following codes will deny if billed more than one (1) unit per 240 days.

Code	Policy
81420	Fetal chromosomal aneuploidy (eg, trisomy 21, monosomy X) genomic sequence analysis panel, circulating cell-free fetal DNA in maternal blood, must include analysis of chromosomes 13, 18, and 21
81507	Fetal aneuploidy (trisomy 21, 18, and 13) DNA sequence analysis of selected regions using maternal plasma, algorithm reported as a risk score for each trisomy

Genetic Codes:

• The following codes will deny if billed more than one (1) unit per 1095 days.

Code	Policy
81528	Oncology (colorectal) screening, quantitative real-time target, and
	signal amplification of 10 DNA markers (KRAS mutations, promoter

methylation of NDRG4 and BMP3) and fecal hemoglobin, utilizing
stool, algorithm reported as a positive or negative result

Genetic Codes:

• The following codes will deny if billed more than once (1) units per lifetime.

Code	Policy
81163	BRCA1 (BRCA1, DNA repair associated), BRCA2 (BRCA2, DNA repair
	associated) (eg, hereditary breast and ovarian cancer) gene
	analysis; full sequence analysis
81225	CYP2C19 (cytochrome P450, family 2, subfamily C, polypeptide 19)
	(eg, drug metabolism), gene analysis, common variants (eg, *2, *3,
	*4, *8, *17)
81226	CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6)
	(eg, drug metabolism), gene analysis, common variants (eg, *2, *3,
	*4, *5, *6, *9, *10, *17, *19, *29, *35, *41, *1XN, *2XN, *4XN)
81227	CYP2C9 (cytochrome P450, family 2, subfamily C, polypeptide 9)
	(eg, drug metabolism), gene analysis, common variants (eg, *2, *3,
	*5, *6)
81296	MSH2 (mutS homolog 2, colon cancer, nonpolyposis type 1) (eg,
	hereditary non-polyposis colorectal cancer, Lynch syndrome) gene
	analysis; known familial variants
81202	APC (adenomatous polyposis coli) (eg, familial adenomatosis
	polyposis [FAP], attenuated FAP) gene analysis; known familial
	variants
81215	BRCA1 (BRCA1, DNA repair associated) (eg, hereditary breast and
	ovarian cancer) gene analysis; known familial variant
81217	BRCA2 (BRCA2, DNA repair associated) (eg, hereditary breast and
	ovarian cancer) gene analysis; known familial variant
81293	MLH1 (mutL homolog 1, colon cancer, nonpolyposis type 2) (eg,
	hereditary non-polyposis colorectal cancer, Lynch syndrome) gene
	analysis; known familial variants
81519	Oncology (breast), mRNA, gene expression profiling by real-time
	RT-PCR of 21 genes, utilizing formalin-fixed paraffin embedded
	tissue, algorithm reported as recurrence score

Questions?

If you have questions, please reach out: Aetna Better Health of Texas

CHIP

Bexar area: 1-866-818-0959 (TTY: 711) Tarrant area: 1-800-245-5380 (TTY: 711)

STAR (Medicaid)

Bexar area: 1-800-248-7767 (TTY: 711) Tarrant area: 1-800-306-8612 (TTY: 711)

STAR Kids

Dallas and Tarrant areas: 1-844-787-5437 (TTY: 711)